Oxford Nanopore wins over Amgen
Oxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company.
French Acticor Biotech raises 15.3m
In a Series B financing round, INSERM spin-off Acticor Biotech has raised 15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical trial of its lead candidate ACT017 in acute ischemic stroke.
HiFiBiO bags immuno-oncology specialist H-Immune
Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, HiFiBiO aims to strengthen its strategic focus on targetting differenct T cell subsets and combat cancer.
Phase III success for Roche breast cancer drug
Roche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.
Targovax reports promising disease-free survival (DFS) data
Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.
EU set to speed up switch to bioeconomy by new action plan
Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Sitryx Therapeutics bags $30m in Series A Financing
Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
Orchard plans to raise US$172m in ADS
British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Sphingotec raises 20m in growth equity financing
Diagnostics company sphingotec GmbH successfully closed a 20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.